Impact of software modeling on the accuracy of perfusion MRI in glioma

American Journal of Neuroradiology

Volumn 36, Issue 12, 2015, Pages 2242-2249

  Hu, L S ^a,d   Kelm, Z ^c   Korfiatis, P ^c   Dueck, A C ^b   Elrod, C ^d   Ellingson, B M ^c   Kaufmann, T J ^c   Eschbacher, J M ^e   Karis, J P ^d,f   Smith, K ^g   Nakaji, P ^g   Brinkman, D ^c   Pafundi, D ^c   Baxter, L C ^d   Erickson, B J ^h  

^a Department of Neurologic Surgery   (South Korea)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d Keller Center for Imaging Innovation   (United States)

^e Departments of Neuropathology   (United States)

^f Departments of Neuroradiology   (United States)

^g BARROW NEUROLOGICAL INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE;

ADULT; ARTICLE; BRAIN BLOOD VOLUME; BRAIN PERFUSION; CALCULATION; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RADIATION NECROSIS; RECEIVER OPERATING CHARACTERISTIC; STEREOTACTIC BIOPSY; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR RECURRENCE; TUMOR VOLUME; AGED; BIOLOGICAL MODEL; BRAIN CIRCULATION; BRAIN TUMOR; COMPUTER ASSISTED DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PERFUSION; PHYSIOLOGY; PROCEDURES; SOFTWARE; VASCULARIZATION;

ADULT; AGED; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; PERFUSION; SOFTWARE;

EID: 84951069138     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A4451     Document Type: Article

References (49)

1. Fink JR, Carr RB, Matsusue E, et al. Comparison of 3 Tesla proton MRspectroscopy,MRperfusion andMRdiffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012;35:56-63 CrossRef Medline
2. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214-21;
3. Erratum in: AJNR Am J Neuroradiol 2004;25:B1
4. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2∗-weighted MR imaging. Radiology 1999;211: 791-98 CrossRef Medline
5. Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078-84 CrossRef Medline
6. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98 Medline
7. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490-98 CrossRef Medline
8. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 2004;101:970-76 CrossRef Medline
9. Hu LS, Eschbacher JM, Heiserman JE, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol 2012;14:919-30 CrossRef Medline
10. Gahramanov S, Muldoon LL, Varallyay CG, et al. Pseudoprogression of glioblastoma after chemo-and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusionMRimaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013;266:842-52 CrossRef Medline
11. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486-96 CrossRef Medline
12. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552-58 CrossRef Medline
13. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: A method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 2010;255:622-28 CrossRef Medline
14. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011;17: 4751-60 CrossRef Medline
15. LaViolette PS, Cohen AD, Prah MA, et al. Vascular change measured with independent component analysis of dynamic susceptibility contrastMRIpredicts bevacizumab response in high-grade glioma. Neuro Oncol 2013;15:442-50 CrossRef Medline
16. Schmainda KM, Prah M, Connelly J, et al. Dynamic-susceptibility contrast agentMRImeasures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 2014;16:880-88 CrossRef Medline
17. Schmainda KM, Zhang Z, Prah M, et al. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015;17:1148-56. CrossRef Medline
18. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859-67 Medline
19. Paulson ES, Schmainda KM. Comparison of dynamic susceptibilityweighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601-13 CrossRef Medline
20. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31: 40-48 CrossRef Medline
21. Emblem KE, Bjornerud A, Mouridsen K, et al. T(1)-and T(2)(∗)-dominant extravasation correction in DSC-MRI, Part II: predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011;31:2054-64 CrossRef Medline
22. Liu HL, Wu YY, Yang WS, et al. Is Weisskoff model valid for the correction of contrast agent extravasation with combined T1 and T2∗ effects in dynamic susceptibility contrast MRI? Med Phys 2011; 38:802-09 CrossRef Medline
23. Quarles CC, Gochberg DF, Gore JC, et al.Atheoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol 2009;54:5749-66 CrossRef Medline
24. Law M, Young R, Babb J, et al. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusionMRimaging with glioma grade. AJNRAmJ Neuroradiol 2006; 27:1975-82 Medline
25. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)∗-weighted contrastenhanced MRI. Magn Reson Med 2004;51:961-68 CrossRef Medline
26. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95 CrossRef Medline
27. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012;72:402-07 CrossRef Medline
28. Roder C, Bender B, Ritz R, et al. Intraoperative visualization of residual tumor: The role of perfusion-weighted imaging in a highfield intraoperative magnetic resonance scanner. Neurosurgery 2013;72(2 suppl operative):ons151-58; discussion ons158 Medline
29. Jain R, Poisson L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2013;267: 212-20 CrossRef Medline
30. Emblem KE, Scheie D, Due-Tonnessen P, et al. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 2008;29:1664-70 CrossRef Medline
31. Gasparetto EL, Pawlak MA, Patel SH, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 2009;250:887-96 CrossRef Medline
32. Hu LS, Eschbacher JM, Dueck AC, et al. Correlations between perfusionMRimaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012;33:69-76 CrossRef Medline
33. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: A conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005;46: 481-89 CrossRef Medline
34. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77: 362-72 Medline
35. Folkerth RD. Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res 2004;117:79-95 CrossRef Medline
36. Wesseling P, van der Laak JA, de Leeuw H, et al. Quantitative immunohistological analysis of the microvasculature in untreated human glioblastomamultiforme: computer-assistedimageanalysis ofwhole-tumor sections. J Neurosurg 1994;81:902-09 CrossRef Medline
37. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96 CrossRef Medline
38. Burger PC, Mahley MS Jr, Dudka L, Vogel FS. The morphologic effects of radiation administered therapeutically for intracranial gliomas: A postmortem study of 25 cases. Cancer 1979;44:1256-72 Medline
39. Forsyth PA, Kelly PJ, Cascino TL, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 1995;82:436-44 CrossRef Medline
40. Louis DN. WHO Classification of Tumors of the Central Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer, World Health Organization; 2007
41. Essig M, Shiroishi MS, Nguyen TB, et al. Perfusion MRI: The five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24-34 CrossRef Medline
42. Falk A, Fahlström M, Rostrup E, et al. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusionMRimaging: A histogram analysis approach. Neuroradiology 2014;56:1031-38 CrossRef Medline
43. Kassner A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: A possible marker of vascular tortuosity. J Magn Reson Imaging 2000;11:103-13 CrossRef Medline
44. Young GS, Setayesh K. Spin-echo echo-planar perfusion MR imaging in the differential diagnosis of solitary enhancing brain lesions: distinguishing solitary metastases from primary glioma. AJNR Am J Neuroradiol 2009;30:575-77 CrossRef Medline
45. Sugahara T, Korogi Y, Kochi M, et al. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001; 22:1306-15 Medline
46. Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004;25: 1524-32 Medline
47. Pathak AP, Schmainda KM, Ward BD, et al. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001;46: 735-47 CrossRef Medline
48. Thuy MN, Kam JK, Lee GC, et al. A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 2015;22:785-99 CrossRef Medline
49. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115: 3-8 CrossRef Medline